Fassett Robert G
The University of Queensland, School of Human Movement Studies, Brisbane, Queensland, Australia.
Clin Interv Aging. 2014 Jan 15;9:191-9. doi: 10.2147/CIA.S39763. eCollection 2014.
The objective of this article is to review the current and emerging treatments of CKD prior to dialysis in the elderly. Worldwide, there are increasing numbers of people who are aged over 65 years. In parallel, there are increasing numbers of elderly patients presenting with chronic kidney disease (CKD), particularly in the more advanced stages. The elderly have quite different health care needs related to their associated comorbidity, frailty, social isolation, poor functional status, and cognitive decline. Clinical trials assessing treatments for CKD have usually excluded patients older than 70-75 years; therefore, it is difficult to translate current therapies recommended for younger patients with CKD across to the elderly. Many elderly people with CKD progress to end-stage kidney disease and face the dilemma of whether to undertake dialysis or accept a conservative approach supported by palliative care. This places pressure on the patient, their family, and on health care resources. The clinical trajectory of elderly CKD patients has in the past been unclear, but recent evidence suggests that many patients over 75 years of age with multiple comorbidities have greatly reduced life expectancies and quality of life, even if they choose dialysis treatment. Offering a conservative pathway supported by palliative care is a reasonable option for some patients under these circumstances. The elderly person who chooses to have dialysis will frequently have different requirements than younger patients. Kidney transplantation can still result in improved life expectancy and quality of life in the elderly, in carefully selected people. There is a genuine need for the inclusion of the elderly in CKD clinical trials in the future so we can produce evidence-based therapies for this group. In addition, new therapies to treat and slow CKD progression are needed for all age groups.
本文的目的是回顾老年人透析前慢性肾脏病(CKD)的现有及新兴治疗方法。在全球范围内,65岁以上的人口数量不断增加。与此同时,患有慢性肾脏病(CKD)的老年患者数量也在增加,尤其是在疾病更晚期阶段。老年人因其合并症、身体虚弱、社会孤立、功能状态差和认知能力下降而有截然不同的医疗保健需求。评估CKD治疗方法的临床试验通常将70 - 75岁以上的患者排除在外;因此,很难将目前推荐给年轻CKD患者的治疗方法应用于老年人。许多患有CKD的老年人会发展为终末期肾病,并面临是否进行透析或接受姑息治疗支持的保守治疗方法的两难境地。这给患者及其家庭以及医疗保健资源带来了压力。过去,老年CKD患者的临床病程并不明确,但最近的证据表明,许多患有多种合并症的75岁以上患者,即使选择透析治疗,其预期寿命和生活质量也会大幅降低。在这种情况下,为一些患者提供姑息治疗支持的保守治疗途径是一个合理的选择。选择进行透析的老年人通常会有与年轻患者不同的需求。在经过精心挑选的人群中,肾脏移植仍可提高老年人的预期寿命和生活质量。未来确实需要将老年人纳入CKD临床试验,以便我们能够为该群体制定基于证据的治疗方法。此外,所有年龄组都需要新的治疗方法来治疗和延缓CKD的进展。